5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
Status:
Completed
Trial end date:
2020-08-19
Target enrollment:
Participant gender:
Summary
This investigation is not only to develop an improved radiation/temozolomide approach, but
also develop a regimen with potential to form the basis of better combined therapy with
immune based treatments.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins